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Abstract
Background: There is an urgent need to discover more sensitive and specific biomarkers to
improve early diagnosis and screen high-risk patients for pancreatic ductal adenocarcinoma
(PDAC). Pancreatic juice is an ideal specimen for PDAC biomarkers discovery, because it is an
exceptionally rich source of proteins released from pancreatic cancer cells.
Methods: To identify novel potential biomarkers for PDAC from pancreatic juice, we carried out
difference gel electrophoresis (DIGE) and tandem mass spectrometry (MS/MS) to compare the
pancreatic juice profiling from 9 PDAC patients and 9 cancer-free controls. Of the identified
differently expressed proteins, three up-regulated proteins in pancreatic cancer juice, matrix
metalloproteinase-9 (MMP-9), oncogene DJ1 (DJ-1) and alpha-1B-glycoprotein precursor (A1BG),
were selected for validation by Western blot and immunohistochemistry. Serum MMP-9 levels
were also detected by enzyme linked immunosorbent assay (ELISA).
Results: Fourteen proteins were up-regulated and ten proteins were down-regulated in cancerous
pancreatic juice compared with cancer-free controls. Increased MMP-9, DJ-1 and A1BG expression
in cancerous pancreatic juice were confirmed by Western blot. Immunohistochemical study
showed MMP-9, DJ-1 and A1BG positively expressed in 82.4%, 72.5% and 86.3% of pancreatic
cancer tissues, significantly higher than that in normal pancreas tissues. Up-regulation of DJ-1 was
associated with better differentiation (p < 0.05). Serum MMP-9 levels were significantly higher in
PDAC (255.14 ng/ml) than those in chronic pancreatitis (210.22 ng/ml, p = 0.009) and healthy
control (203.77 ng/ml, p = 0.027).
Conclusion: The present proteome analysis revealed MMP-9, DJ-1 and A1BG proteins as elevated
in pancreatic juice from PDAC, which suggest their further utility in PDAC diagnosis and screening.
This is the first time A1BG was identified as a potential biomarker in pancreatic cancer associated
samples. The measurement of serum MMP-9 might be clinically useful for PDAC diagnosis.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is the fourth
or fifth most common cause of cancer-related mortality
worldwide. Because of late presentation and rapid aggres-
siveness, most PDAC cases are diagnosed at late stage, and
its prognosis is accordingly poor. So detection of PDAC at
an early disease stage is critical for successful clinical ther-
apy. Carbohydrate antigen (CA) 19-9 is the most com-
monly used tumor marker for PDAC, but it lacks
satisfactory sensitivity and specificity, especially in early
diagnosis [1,2]. There is an urgent need to discover more
sensitive and specific biomarkers to improve early diagno-
sis and screen high-risk patients for PDAC [3].
The proteomic approach is a powerful tool to identify
novel biomarkers or therapeutic targets from cancer-asso-
ciated samples. Pancreatic juice is an ideal specimen in
proteomic studies, because it is an exceptionally rich
source of proteins which are released from pancreatic cells
in the physiological state and in pathological conditions
[4]. It is reasonable that biomarkers identified in pancre-
atic juice could subsequently be measured in more acces-
sible specimens such as serum. Therefore, mining
pancreatic juice proteome might help to identify novel
protein markers for pancreatic diseases such as pancreatic
cancer.
Recently, many efforts have been made to analyze pancre-
atic juice by proteomic methods. Rosty et al. [5] identified
hepatocarcinoma-intestine-pancreas/pancreatitis-associ-
ated protein I (HIP/PAP-I) as a biomarker for PDAC by
surface enhanced laser desorption ionization (SELDI)
techonology. Chen et al. [6] used isotope-code affinity tag
(ICAT) technology to compare the pancreatic juice pro-
tein profiling from pancreatitis patients and normal con-
trols. Gronborg et al. [3] used one-dimensional
electrophoresis combined with liquid chromatography
tandem mass spectrometry (1-DE-LC-MS/MS) to identify
a total of 170 unique proteins in pancreatic juices from 3
cases of PDAC patients, and confirmed PAP-2 as a novel
marker for PDAC.
In the current study, we characterized the pancreatic juice
protein profiling in PDAC compared with cancer-free con-
trols using difference gel electrophoresis (DIGE) and tan-
dem mass spectrometry (MS/MS), and identified a
number of novel protein markers in pancreatic juice
which might be a promising target for pancreatic cancer
diagnosis and screening.
Methods
Patients and samples
The study was approved by the Ethical   Commitee of
Shandong Academy of Medical Science. Fresh pancreatic
juice samples were collected with informed consent from
9 PDAC patients and 9 cancer-free controls undergoing
endoscopic retrograde cholangiopancreatography (ERCP)
in Qilu Hospital and Qianfoshan Hospital of Shandong
University. Clinical data of the patients included were
summarized in Table 1. After collection, the pancreatic
juice samples were centrifuged at 10,000 rpm for 20 min
at 4°C and supernatant of each was aliquoted and stored
at -80°C until used.
Pancreatic juice protein extraction
Pancreatic juice samples were first precipitated with ace-
tone. Briefly, 1.2 mL cold acetone (Fluca) was added to
300 μL pancreatic juice and kept at -20°C for 2 hours,
then centrifuged at 13,000 rpm for 10 min at 4°C. Super-
natant was discarded and pellet was dissolved in 500 μL
of lysis buffer containing 30 mM Tris, 8 M urea, 2 M thiou-
rea, 2% 3-[(3-cholamidopropyl) dimethylammonio]-1-
propanesulfonate (CHAPS), 18 mM dithiothreitol (DTT)
and 0.5% IPG Buffer (GE Healthcare). The mixture was
then centrifuged at 12,000 rpm for 10 min at 4°C, and the
supernatant was collected and stored at -80°C. Protein
concentration was determined using a 2-D Quant Kit
according to the manufacturer's instruction (GE Health-
care).
Two-dimensional gel electrophoresis (2-DE)
Cancerous or control pancreatic juice protein extracts
were first pooled for traditional 2-DE. Two hundred
micrograms of each pooled protein sample was diluted in
450 μL rehydration buffer (7 M urea, 2 M thiourea, 4%
CHAPS, 0.5% IPG buffer, 0.002% bromophenol blue).
Isoelectric focusing was performed on Ettan IPGphor (GE
Healthcare) with 24 cm IPG strips (pH 3–10 NL, GE
Healthcare). The IPG strips were first rehydrated at 30 V
for 12 hours, then focused at 500 V for 1 hour, 1,000 V for
1 hour, and maintained at 8,000 V until a total of 65,000
Vhr was arrived. After isoelectric focusing, the strips were
equilibrated with 0.375 M Tris-HCl (pH 8.8), 6 M urea,
20% glycerol, 2% sodium dodecyl sulfate (SDS), and
0.2% bromophenol blue. IEF strips were first treated with
130 mM DTT for 10 min, followed by 135 mM iodoaceta-
mide for 10 min with constant shaking. The equilibrated
strips were transferred to 12.5% SDS polyacrylamide gel
electrophoresis (SDS-PAGE) on Ettan DALT twelve system
(GE Healthcare) with constant power (0.2 W/gel, 1 hour;
1.7 W/gel, 4.5 hours) at 20°C. All gels were stained with
Coomassie blue R350 (GE Healthcare), and scanned
using a PowerLook 2100 XL scanner system (Umax USA).
Two-dimensional difference gel electrophoresis (DIGE)
Fifty micrograms of each of cancerous and cancer-free
control pancreatic juice protein extracts was minimally
labeled with 400 pmol Cy3 or 400 pmol Cy5 fluorescent
dye (GE Healthcare). An internal standard pool generated
by combining equal amounts of extracts from all the sam-BMC Cancer 2008, 8:241 http://www.biomedcentral.com/1471-2407/8/241
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ples was labeled with 400 pmol Cy2. The labeling reaction
was carried out in the dark on ice for 30 min, and
quenched with 10 mM lysine for 10 min. 2-DE was per-
formed as described above, except that low-fluorescent
glass plates were used. The Cy2, Cy3, and Cy5-labeled
images were acquired on a Typhoon Trio scanner (GE
Healthcare) at the excitation/emission of 488/520 nm,
532/580 nm and 633/670 nm, respectively.
Trypsin digestion and MALDI-TOF-MS and MS/MS
Spots of interest were excised from gels stained by
Coomassie Blue R350, and were digested with sequencing
grade modified porcine trypsin (Promega) as described
previously [7]. Subsequent protein identification was car-
ried out on the ABI 4700 Proteomic Analyzer MALDI-
TOF-MS/MS mass spectrometry (Applied Biosystems,
USA) on a reflective mode. Peptide mass fingerprint
(PMF) was acquired between 800–3500 Da. The strongest
five peaks from PMF were selected to obtain MS/MS spec-
tra. PMF and MS/MS data were then searched against a
human subset of the Swiss-Prot database using GPS
explorer software (Applied Biosystems, USA).
Western blot
Thirty micrograms of pancreatic juice protein extracts
from 6 PDAC and 6 cancer-free controls were used for
SDS-PAGE. The separated proteins were transferred to
nitrocellulose membranes (GE Healthcare). The mem-
branes were blocked for 1 hour and incubated with anti-
DJ-1 antibody (1:1000 dilutions, MBL international cor-
poration, MA), anti-MMP-9 antibody (1:1000 dilutions,
Santa Cruz Biotechnology) and anti-A1BG antibody
(1:1000 dilutions, Aviva System Biology, San Diego, CA)
overnight at 4°C. After peroxidase-conjugated secondary
antibody was added, proteins were detected using an ECL
Plus kit (GE Healthcare).
Immunohistochemical analysis (IHC)
To study the tissue compartment for DJ-1, MMP-9 and
A1BG, a tissue array (Chaoying Biotechnology co. Xian,
China) containing 51 cases of PDAC and 8 adjacent nor-
mal pancreas tissues was used in immunohistochemical
analysis. Clinicopathological data of the tissue array were
summarized (Table 2). Paraffin-embedded tissue array
slides were processed for antigen retrieval using micro-
wave heating in citrate buffer, and immunohistochemi-
cally stained with the same antibodies used in Western
blot analysis at 1:100 dilution. Visualization was per-
formed using ABC kit according to the manufacturer's rec-
ommendation (Zhongshan Bio co., Beijing, China).
Enzyme linked immunosorbent assay (ELISA)
Serum from 8 PDAC patients, 9 chronic pancreatitis
patients and 8 healthy controls not included in the pro-
teomic analysis were collected for MMP-9 ELISA analysis.
Serum levels of human MMP-9 were analyzed with a com-
mercially available kit (Biotrak) according to the manu-
facturer's recommendation. Serum samples were diluted
Table 1: Clinicopathological data of PDAC patients and cancer-free controls in proteomic analysis
No. of samples Sex Age Histology* Tumor location Metastases
PDAC
1 female 55 Moderately differentiated ductal adenocarcinoma Tail of pancreas Yes
2 male 65 Well differentiated ductal adenocarcinoma Head of pancreas No
3 male 38 Well differentiated ductal adenocarcinoma Head of pancreas Yes
4 male 57 Moderately differentiated ductal adenocarcinoma Body of pancreas Yes
5 female 53 Poorly differentiated ductal adenocarcinoma Head of pancreas No
6 male 59 Moderately differentiated ductal adenocarcinoma Head of pancreas Yes
7 female 44 Moderately differentiated ductal adenocarcinoma Tail of pancreas Yes
8 female 51 Well differentiated ductal adenocarcinoma Head of pancreas No
9 male 48 Moderately differentiated ductal adenocarcinoma Tail of pancreas No
Cancer-free Clinical diagnosis
1 male 53 Chronic pancreatitis
2 female 66 benign cystic neoplasm of pancreas
3 male 49 Gallstone pancreatitis
4 male 50 Chronic pancreatitis
5 female 52 benign cystic neoplasm of pancreas
6 female 57 benign cystic neoplasm of pancreas
7 male 46 Chronic pancreatitis
8 female 47 cystic fibrosis of pancreas
9 male 60 Chronic pancreatitis
* PDAC differentiation was classified according to the WHO standard (2nd edition, 1996).BMC Cancer 2008, 8:241 http://www.biomedcentral.com/1471-2407/8/241
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Table 2: Data of tissue array included in immunohistochemical analysis
No. of samples Age Sex Histology Grade
1 64 Male Moderately differentiated ductal adenocarcinoma II
2 64 Male Poorly differentiated ductal adenocarcinoma III
3 64 Male Moderately differentiated ductal adenocarcinoma II
4 62 Female Poorly differentiated ductal adenocarcinoma III
5 62 Female Poorly differentiated ductal adenocarcinoma III
6 62 Female Poorly differentiated ductal adenocarcinoma III
7 12 Female Normal pancreatic tissue -
8 12 Female Normal pancreatic tissue -
9 12 Female Normal pancreatic tissue -
10 49 Male Poorly differentiated ductal adenocarcinoma III
11 49 Male Moderately differentiated ductal adenocarcinoma II
12 49 Male Moderately differentiated ductal adenocarcinoma II
13 69 Female Moderately differentiated carcinoma II
14 69 Female Moderately differentiated carcinoma II
15 69 Female Well differentiated Mucinous adenocarcinoma I
16 73 Female Poorly differentiated ductal adenocarcinoma III
17 73 Female Poorly differentiated ductal adenocarcinoma III
18 73 Female Poorly differentiated carcinoma III
19 49 Male Moderately differentiated ductal adenocarcinoma II
20 49 Male Moderately differentiated ductal adenocarcinoma II
21 49 Male Moderately differentiated ductal adenocarcinoma II
22 67 Male Poorly differentiated ductal adenocarcinoma III
23 67 Male Poorly differentiated ductal adenocarcinoma III
24 67 Male Poorly differentiated ductal adenocarcinoma III
25 68 Female Moderately differentiated ductal adenocarcinoma II
26 68 Female Moderately differentiated ductal adenocarcinoma II
27 68 Female Moderately differentiated ductal adenocarcinoma II
28 51 Female Moderately differentiated ductal adenocarcinoma II
29 51 Female Poorly differentiated ductal adenocarcinoma III
30 51 Female Poorly differentiated ductal adenocarcinoma III
31 45 Male Well differentiated ductal adenocarcinoma I
32 45 Male Well differentiated ductal adenocarcinoma I
33 45 Male Well differentiated ductal adenocarcinoma I
34 60 Male Poorly differentiated ductal adenocarcinoma III
35 60 Male Poorly differentiated ductal adenocarcinoma III
36 60 Male Moderately differentiated ductal adenocarcinoma II
37 65 Male Poorly differentiated ductal adenocarcinoma III
38 65 Male Poorly differentiated ductal adenocarcinoma III
39 65 Male Moderately differentiated ductal adenocarcinoma II
40 55 Male Poorly differentiated ductal adenocarcinoma III
41 55 Male Poorly differentiated ductal adenocarcinoma III
42 55 Male Poorly differentiated ductal adenocarcinoma III
43 70 Male Well differentiated ductal adenocarcinoma I
44 70 Male Moderately differentiated ductal adenocarcinoma II
45 70 Male Well differentiated ductal adenocarcinoma I
46 30 Male Normal pancreatic tissue -
47 30 Male Normal pancreatic tissue -
48 51 Female Well differentiated ductal adenocarcinoma I
49 51 Female Well differentiated ductal adenocarcinoma I
50 51 Female Well differentiated ductal adenocarcinoma I
51 62 Female Moderately differentiated papillary carcinoma II
52 62 Female Moderately differentiated ductal adenocarcinoma II
53 62 Female Moderately differentiated ductal adenocarcinoma II
54 50 Male Poorly differentiated ductal adenocarcinoma III
55 50 Male Poorly differentiated ductal adenocarcinoma III
56 50 Male Poorly differentiated ductal adenocarcinoma III
57 33 Female Normal pancreatic tissue -
58 14 Female Normal pancreatic tissue -
59 38 Female Normal pancreatic tissue -BMC Cancer 2008, 8:241 http://www.biomedcentral.com/1471-2407/8/241
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at 1:100; all assays were done in duplicate. The sensitivity
limit of MMP-9 ELISA was 0.08 ng/ml.
Data analysis
DIGE images were analyzed by ImageMaster 6.0 DIGE-
enable software (GE Healthcare). The best internal stand-
ard image was assigned as the master reference. The pro-
tein spots on the remaining internal standard images were
matched to the master reference to ensure that the same
protein spots were compared between gels. Spot intensity
was normalized by dividing each Cy3 or Cy5 spot volume
with the corresponding Cy2 (internal standard) spot vol-
ume. Statistical analyses were performed using SPSS 13.0
software. The relationships with DJ-1, MMP-9 and A1BG
expression and clinicopathological parameters were ana-
lyzed using Chi-square or Fisher's exact tests. The differ-
ences of MMP-9 levels in serum among the various groups
were analyzed using independent-samples t-test. p < 0.05
was considered to be statically significant.
Results
Differentially expressed Proteins in pancreatic juice from 
PDAC and cancer-free controls
Given the limited amount of pancreatic juice sample
available, we first made sample pools of all cancerous and
cancer-free control pancreatic juice protein extracts sepa-
rately to identify the differently expressed proteins by tra-
ditional 2-DE. Each pool was repeated three times.
Coomassie blue R350 staining was applied to visualize
the protein spots, because of its compatibility with pro-
tein identification by MS. Moreover, we carried out DIGE
on each individual sample to verify differential protein
expression found by the traditional 2-DE. Most spot
changes in DIGE analysis were consistent with those
found in Coomassie blue stained 2-DE analysis (Figure 1).
Twenty four proteins with more than two-fold expression
change between pancreatic cancer juice and cancer-free
pancreatic juice were identified (Table 3). Fourteen pro-
teins were significantly up-regulated and ten proteins were
significantly down-regulated in pancreatic cancer juice
compared with the cancer-free controls (Figure 2). Three
up-regulated proteins MMP-9, DJ-1 and A1BG were fur-
ther confirmed by Western blot and immunohistochemis-
try.
Western blot analysis of MMP-9, DJ-1 and A1BG
As seen in Figure 3, compared with cancer-free controls,
increased MMP-9, DJ-1 and A1BG expression in cancerous
pancreatic juice were detected by Western blot. In addi-
tion, cancerous pancreatic juice with MMP-9 expression
evinced both 92 kDa and 82 kDa bands, corresponding to
the latent and activated forms of MMP-9, respectively.
Immunohistochemical validation of MMP-9, DJ-1 and 
A1BG
The expressions of MMP-9, DJ-1 and A1BG were con-
firmed by immunohistochemistry in 51 pancreatic cancer
and 8 normal pancreas samples that were not included in
the proteomic experiment (Table 4; Figure 4). MMP-9 was
detected in the malignant ductal epithelia in 82.4% of
PDAC tissues, but was barely detectable in normal pan-
creas. In addition, 9 cases of PDAC demonstrated strong
MMP-9 expression in the stroma.
In normal pancreas, DJ-1 was negatively or weakly
expressed in duct epithelium, acinar cells and islet cells. In
PDAC, 72.5% demonstrated DJ-1 over-expression in can-
cer cells. In addition, DJ-1 over-expression was related to
the differentiation of PDAC. DJ-1 positive stain was
observed in 7/9 well differentiated tumors, 16/19 moder-
ately differentiated tumors, and 14/23 poorly differenti-
ated tumors, respectively. There was a significant
difference of DJ-1 over-expression between moderately
differentiated PDAC with poorly differentiated PDAC (p <
0.05).
No positive A1BG staining was detected in all the normal
pancreas tissues. A1BG was over-expressed in the cyto-
plasma of malignant epithelia in 86.3% of pancreatic can-
cer tissues, significantly higher than that in normal
pancreas tissues (p < 0.01).
Serum MMP-9 levels by ELISA
As shown in Figure 5, serum MMP-9 levels were signifi-
cantly higher in patients with pancreatic cancer (median =
255.14 ng/ml; quartile range, 125.43 ng/ml) than those
with chronic pancreatitis (median = 210.22 ng/ml; quar-
tile range, 12.48 ng/ml; p = 0.009) and normal controls
(median = 203.77 ng/ml; quartile range, 17.04 ng/ml; p =
0.027).
Discussion
PDAC is the most common pathological subgroup of pan-
creatic cancer. During the development of PDAC, malig-
nant ductal cells preferentially shed into the ductal lumen,
making pancreatic juice a rich source of cancer-specific
proteins. Therefore, pancreatic juice is an ideal specimen
for identifying new tumor markers for PDAC.
We adopted a quantitative proteomic technology (DIGE)
to compare the protein profiling of pancreatic juice from
PDAC and its cancer-free controls. DIGE technology not
only provided reliable quantification, but also can mini-
mize the run-to-run reproducibility of conventional 2-DE
[8]. In this study, a total of 24 differentially expressed pro-
teins between pancreatic juice from PDAC and cancer-free
controls, including 14 up-regulated proteins and 10
down-regulated proteins, were identified. Half of the up-BMC Cancer 2008, 8:241 http://www.biomedcentral.com/1471-2407/8/241
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Table 3: Differentially expressed proteins in pancreatic juice from PDAC patients and cancer-free controls (with and without 
pancreatitis)
Spot position Protein Name MW(Da) PI Mascot PMF 
Score
Sequence 
Coverage (%)
Protein Species 
Score (C.I.%)
Fold change
PDAC/Cancer-
free controls
Pancreatitis/No 
pancreatitis 
controls
1406 Alpha-1-antitrypsin 
precursor
46737 5.37 298 39.788 100 3.43 -1.72
1394 Serum albumin 
precursor
69367 5.92 491 73.493 100 2.67 -1.27
2106 Apolipoprotein A-I 
precursor
30778 5.56 289 56.054 100 4.83 1.30
1652 Glutathione S-
transferase P
32311 5.43 90 68.249 99.998 3.84 -1.36
1312 Alpha-1B-
glycoprotein 
precursor
54273 5.58 124 33.863 100 2.39 -1.37
1471 Vitamin D-binding 
protein precursor
52964 5.40 300 60.622 100 5.60 -2.03
2193 Cationic 
antimicrobial 
protein
26886 9.75 127 38.512 99.997 2.73 -3.90
2196 Superoxide 
dismutase [Mn], 
mitochondrial 
precursor
24722 8.35 109 36.524 100 2.54 2.12
1543 Serotransferrin 
precursor
77050 6.81 519 76.674 100 5.09 1.03
1971 Ig lambda chain V-
IV region Hil
11517 6.04 102 49.056 100 2.66 1.44
1253 matrix 
metalloproteinase-
9
78427 5.69 214 32.458 100 3.67 -1.03
1318 Hemopexin 
precursor
51676 6.55 213 42.289 100 3.23 1.06
2155 Oncogene DJ1 19891 6.33 114 15.878 100 2.59 -1.25
1739 Fibrinogen beta 
chain precursor
55928 8.54 247 53.067 100 4.15 -2.56
2048 Trypsin-1 
precursor
26558 6.08 121 35.176 100 -2.64 2.80
1807 Carboxypeptidase 
A2 precursor
46828 5.68 208 52.449 100 -13.00 1.41
2007 Complement C4-B 
precursor
192793 6.73 123 31.488 100 -2.10 -1.50
2114 Chymotrypsinogen 
B precursor
27870 6.79 146 36.051 100 -2.43 1.30
2052 Elastase-3A 
precursor
29475 6.43 143 35.156 100 -5.71 -1.80
2030 Elastase-3B 
precursor
29293 5.65 157 42.945 100 -2.30 1.12
1967 Fibrinogen-like 
protein 1 
precursor
36392 5.58 196 57.347 100 -2.71 -1.51
1857 Haptoglobin 
precursor
45205 6.13 163 45.013 100 -2.00 -1.72
2064 Trypsin-3 
precursor
32499 7.46 120 27.118 100 -2.82 3.20
2129 Complement C3 
precursor
187148 6.02 248 54.849 100 -3.78 4.04BMC Cancer 2008, 8:241 http://www.biomedcentral.com/1471-2407/8/241
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regulated proteins in PDAC, such as DJ-1, MMP-9, apoli-
poprotein A-I, A1BG, SOD [Mn], serotransferrin and Ig
lambda chain V-IV region were firstly identified in cancer-
ous pancreatic juice. Three up-regulated proteins MMP-9,
DJ-1 and A1BG in PDAC pancreatic juice were further val-
idated. Western blot analysis demonstrated elevated pro-
tein levels of MMP-9, DJ-1 and A1BG in cancerous
pancreatic juice compared with cancer-free pancreatic
juice, which is consistent with our proteomic findings.
For the scarcity of cancer-free pancreatic juice specimens,
two types of pancreatic juice control subjects, one with
pancreatitis and the other without pancreatitis, were
included in our study. In a previous proteomic study by
Shen et al. [9], it was demonstrated that there are obvious
differences in protein profiling between pancreatitis and
healthy control tissues. So the protein profiling of pancre-
atic juice between pancreatitis patients and control sub-
jects without pancreatitis was also compared (Table 3).
Seven pancreatic juice proteins, such as trypsin-1 precur-
sor, were demonstrated to be differently expressed
between cancer-free controls with and without pancreati-
tis. In addition, five down-regulated proteins identified in
pancreatic cancer juice (carboxypeptidase A2, chymot-
rypsinogen B, elastase-3A, elastase-3B and trypsin-1) was
also down-regulated in pancreatic cancer tissues com-
pared with pancreatitis and normal pancreas tissues as
described by Shen et al. [9].
Representative gel images of proteins extracted from pancreatic cancer juice and cancer-free controls juice Figure 1
Representative gel images of proteins extracted from pancreatic cancer juice and cancer-free controls juice. 
Representative 2-DE gel images of pancreatic juice proteins from PDAC (A) and cancer-free controls (B), and representative 
DIGE overlay image (C). Labeled spots are significantly up-regulated proteins in pancreatic cancer juice (A), in cancer-free con-
trols juice (B) and a total of 24 differentially expressed protein spots (C).BMC Cancer 2008, 8:241 http://www.biomedcentral.com/1471-2407/8/241
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Individual differentially expressed protein spots in pancreatic cancer juice and cancer-free controls juice Figure 2
Individual differentially expressed protein spots in pancreatic cancer juice and cancer-free controls juice. 
Selected areas of 14 up-regulated (A) and 10 down-regulated (B) spots and their corresponding DIGE images.BMC Cancer 2008, 8:241 http://www.biomedcentral.com/1471-2407/8/241
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Over-expression of MMP-9 and DJ-1 in pancreatic cancer
tissues have been shown in previous studies [10,11]. It is
believed that MMP-9 over-expression results in the degra-
dation of the basement membrane and contributes to
local invasion or distant metastases during pancreatic car-
cinogenesis [12,13]. DJ-1 is a novel mitogen-dependent
oncogene involved in ras-related signal transduction
pathway [14]. Recently, several previous studies have
shown that DJ-1 is over-expressed in multiple cancer tis-
sues including pancreatic cancer [15,16]. Our immuno-
histological study extended the above investigation to
larger sample size and revealed that MMP-9 and DJ-1 were
expressed in 82.4% and 72.5% of PDAC tissues, signifi-
cantly higher than that in normal pancreas. Furthermore,
DJ-1 over-expression was associated with PDAC differen-
tiation. Moderately differentiated PDAC demonstrated a
higher expression level of DJ-1 than poorly differentiated
MMP-9, DJ-1 and A1BG expression analysis by Western blot Figure 3
MMP-9, DJ-1 and A1BG expression analysis by Western blot. Increased MMP-9 (A), DJ-1 (B) and A1BG (C) were 
detected in the cancerous juice samples compared with cancer-free pancreatic juice samples; MMP-9 expression evinced both 
92 kDa and 82 kDa bands, corresponding to the latent and activated forms of MMP-9, respectively.
Table 4: Summary of MMP-9, DJ-1 and A1BG immunohistochemical study on PDAC tissue array
PDAC Negative Positive Total
MMP-9 DJ-1 A1BG MMP-9 DJ-1 A1BG
Well differentiated 2 (22.2%) 2 (22.2%) 1 (11.1%) 7 (77.8%) 7 (77.8%) 8 (88.9%) 9
Moderately differentiated 2 (10.5%) 3 (15.8%) 2 (10.5%) 17 (89.5%) 16 (84.2%) 17 (89.5%) 19
Poorly differentiated 5 (21.7%) 9 (39.1%) 4 (17.4%) 18 (78.3%) 14 (60.9%) 19 (82.6%) 23BMC Cancer 2008, 8:241 http://www.biomedcentral.com/1471-2407/8/241
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tumor subgroup, which suggests that DJ-1 may be a differ-
entiation related protein.
A1BG, a member of the immunoglobulin superfamily, is
believed to be a secreted plasma protein, but its function
is unknown [17]. In this study, we first identified and con-
firmed A1BG as an elevated protein in pancreatic juice
and cancer tissues of PDAC. Our immunohistochemical
study further validated that A1BG protein over-expression
was seen in most PDAC tissues, but not detected in nor-
mal pancreas tissues. Using a glycoprotein profiling
method, Kreunin et al. [18] recently found that A1BG was
detected in urinary samples from bladder cancer patients,
but in none of the samples obtained from non-tumor-
bearing individuals. Yoon et al. [19] also demonstrated
A1BG over-expression in liver cancer cell lines and tissues
by semi-quantitative RT-PCR. These findings together
with our proteomic results suggest that A1BG might be a
cancer-associated gene and a novel tumor marker of can-
cer, and its possible functions in carcinogenesis deserve
further investigation.
The novel protein biomarkers identified in ERCP-
obtained pancreatic juice might have enormous potential
for use in the diagnosis of PDAC. It is reasonable to
believe that proteins indicative of cancer in pancreatic
juice are also elevated in blood. Therefore, we measured
serum levels of MMP-9 in PDAC, and found that serum
MMP-9 had a higher level in PDAC than in chronic pan-
creatitis and healthy controls. The findings suggest that
serum measurement of MMP-9 or other up-regulated pro-
teins in cancerous pancreatic juice might be helpful in the
diagnosis of pancreatic adenocarcinoma and deserve fur-
ther investigation.
Conclusion
In the present study, we carried out a comparative pro-
teomics analysis on pancreatic juice from PDAC and its
cancer-free controls. A total of 24 differentially expressed
proteins were identified, of which 14 were over-regulated
and 10 were under-regulated in pancreatic juice of PDAC.
We further confirmed the expression levels of three up-
regulated proteins (MMP-9, DJ-1 and A1BG) in pancreatic
juice, tissue and serum samples using Western blot, IHC
or ELISA. A1BG was firstly identified as a biomarker in
cancer-associated samples. Serum MMP-9 measurement
might be helpful in discriminating pancreatic adenocarci-
noma from chronic pancreatitis and healthy controls. The
newly identified proteins in this study might be useful for
developing new pancreatic juice-related or serum-related
diagnostic markers for PDAC.
MMP-9, DJ-1 and A1BG expression analysis by Immunohisto- chemistry (×200) Figure 4
MMP-9, DJ-1 and A1BG expression analysis by Immu-
nohistochemistry (×200). MMP-9 (A), DJ-1 (C) and A1BG 
(E) over-expressed in PDAC tissues. MMP-9 (B), DJ-1(D) and 
A1BG (F) were not detectable in normal pancreas tissues.
Box plot of MMP-9 serum levels for PDAC, chronic pancrea- titis and normal controls by ELISA Figure 5
Box plot of MMP-9 serum levels for PDAC, chronic 
pancreatitis and normal controls by ELISA. The serum 
levels of MMP-9 in PDAC patients were significantly higher 
than those in chronic pancreatitis patients and in healthy con-
trols (p < 0.05). PDAC: pancreatic ductal adenocarcinoma 
patients; CP: chronic pancreatitis patients; N: healthy con-
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